Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...

Dr A Bush, Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK email:a.bush{at}rbh.nthames.nhs.uk BACKGROUND The addition of long acting inhaled β ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

BACKGROUND The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of ...

Salmeterol (as xinafoate) 50mcg/inh; dry pwd for inhalation; device with drug in blisters. Serevent Diskus is supplied as a disposable teal green plastic inhaler containing a foil blister strip ...

Since 2010 the World Anti-Doping Agency (WADA) has changed their restrictions towards certain beta2-agonists on the prohibited list. As of 2013, the beta2-agonists salbutamol, formoterol and ...

Fluticasone propionate, salmeterol (as xinafoate) 55mcg/14mcg, 113mcg/14mcg, 232mcg/14mcg; per actuation; dry pwd for oral inh with a dose counter; contains lactose. Increased risk of asthma ...